Weitzel J N
Department of Clinical Cancer Genetics, City of Hope National Medical Center, Duarte, CA 91010, USA.
Curr Opin Obstet Gynecol. 1999 Feb;11(1):65-70. doi: 10.1097/00001703-199901000-00012.
Few advances in medical science have yielded as much publicity and controversy as discoveries in genetics. Moving quickly from the bench to the bedside, genetic testing for inherited susceptibility to breast and ovarian cancer has had a significant impact on our paradigms for decisions about the treatment and prevention of disease. Assessment of cancer risk is developing into a distinct discipline, with rapidly evolving genetic technologies and models for estimating an individual's risk of cancer. Exciting developments in chemoprevention of breast cancer demonstrate the potential to offer a broader range of options for decreasing cancer risk. This article will consider recent advances in the understanding of cancer genetics, and describe the state-of-the-art in terms of management of individuals with inherited susceptibility to breast and ovarian cancer.
医学科学领域中，很少有进展能像遗传学发现那样引发如此多的关注和争议。从实验室迅速应用到临床，针对遗传性乳腺癌和卵巢癌易感性的基因检测，对我们关于疾病治疗和预防的决策模式产生了重大影响。癌症风险评估正发展成为一门独特的学科，随着基因技术和估算个体癌症风险模型的迅速发展。乳腺癌化学预防方面令人兴奋的进展表明，有可能提供更广泛的降低癌症风险的选择。本文将探讨癌症遗传学理解方面的最新进展，并描述遗传性乳腺癌和卵巢癌易感性个体管理的最新状况。
